Progenics Pharmaceuticals, Inc. (PGNX) said Thursday that it has priced an underwritten public offering of 11 million primary shares of its common stock at a public offering price of $2.00 per share.
The gross proceeds from the sale of the shares, before underwriting discounts and commissions and other offering expenses, are expected to be about $22 million.
The company has also granted the underwriter a 30-day option to purchase 1.65 million additional shares of common stock.
The offering is expected to close on or about December 4.
All of the shares sold in the offering are being sold by Progenics, with the proceeds to be used for research and development and general corporate purposes.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.